PSMA PET/CT Scan Reduces Need for Prostate Cancer Biopsies by 50% - Summary - MDSpire
Clinical Guidelines

PSMA PET/CT Scan Reduces Need for Prostate Cancer Biopsies by 50%

A PSMA-11 PET/CT scan with gallium Ga-68 led to the identification of more aggressive prostate cancer cells in men with equivocal or nonsuspicious findings on multiparametric MRI than a standard biops...

Share

The phase III PRIMARY2 trial evaluated the efficacy of PSMA-11 PET/CT scans with gallium Ga-68 in detecting aggressive prostate cancer in men with previously equivocal multiparametric MRI results. Conducted across seven Australian hospitals with 660 participants, the study demonstrated that PSMA PET/CT reduced the need for biopsies by half and minimized the diagnosis of insignificant cancers without missing significant cases. The findings, shared by co-leads Louise Emmett and James Buteau, suggest a substantial advancement in prostate cancer diagnostics, showing potential benefits in reducing anxiety associated with unnecessary procedures.

Original Source(s)

PSMA PET/CT Scan Reduces Need for Prostate Cancer Biopsies by 50%

  • by The ASCO Post Staff

  • April 14, 2026

Related Content

Mass Spec Roundup: From Masterpieces to Microplastics

Advances in imaging, AI, and single-cell analysis reveal hidden chemistry in art, biology, and the environment

  • April 15, 2026

  • 6 min
From Spectra to Structure: An Interview with Novogaia’s Tess Bevers

Novogaia’s transformer-based model converts untargeted mass spectra into structural predictions for early-stage drug discovery

Cell and Gene Roundup: CAR T Breaks New Ground

A campus-built therapy enters clinical trials as researchers refine gene editing and uncover new ways to control gene expression

  • April 15, 2026

  • 6 min